List view / Grid view
23 September 2021 | By Dr Andrea Pfeifer (AC Immune)
Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
10 July 2023 | By Xiao Xu
Central nervous system (CNS) research is making breakthroughs with innovative therapies and next-generation technologies. Researchers are now able to use human tissue to identify relevant novel drug targets and biomarkers for a broad range of CNS diseases including schizophrenia, Alzheimer’s disease and Parkinson’s disease. As our understanding of the brain…
3 February 2021 | By Hannah Balfour (Drug Target Review)
A new study suggests bile acids may act as a valuable biomarker for diagnosing and tracking the progression of Parkinson's disease.
28 May 2021 | By Victoria Rees (Drug Target Review)
Scientists have shown that trapped LC3B protein in brain cells enables Parkinson's disease to spread, presenting a drug target.
5 September 2023 | By Taylor Mixides (Drug Target Review)
A growing body of evidence pinpoints neuroinflammation as a pivotal factor driving brain-related pathogenesis. Yet, a crucial question lingers: among the various immune cell groups residing within the brain, which one orchestrates this inflammatory reaction?
24 February 2021 | By Victoria Rees (Drug Target Review)
Researchers have developed a workflow to study the behaviour of C. elegans in a high-throughput screen to identify Parkinson's disease drugs.
3 November 2023 | By Drug Target Review
In rodent and nonhuman primate animals, circuit-specific gene therapy offers promise for Parkinson’s disease and other brain disorders.
19 September 2024 | By Kristina Torfgard (IRLAB Therapeutics)
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
14 June 2021 | By Victoria Rees (Drug Target Review)
Researchers have shown that the leakage of mitochondrial double-stranded DNA into the cell can contribute to Parkinson's disease.
29 October 2021 | By Anna Begley (Drug Target Review)
A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
24 June 2022 | By Ria Kakkad (Drug Target Review)
NRG is developing a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease and motor neuron disease.
4 August 2021 | By Anna Begley (Drug Target Review)
Researchers used an experimental small molecule that helped restore the removal of damaged mitochondria from brain cells in a mouse model of Parkinson's.
14 October 2021 | By Anna Begley (Drug Target Review)
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
13 May 2022 | By Ria Kakkad (Drug Target Review)
In a new study, researchers describe a process for converting non-neuronal cells into functioning neurons able to restore capacities undermined by Parkinson’s destruction of dopaminergic cells.
3 November 2021 | By Anna Begley (Drug Target Review)
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
